This segment focused on the research, development, and clinical trials of biosimilar monoclonal antibodies. Epirus aimed to create cost-effective alternatives to existing biologic drugs for various inflammatory diseases. The company utilized advanced biotechnology and analytical methodologies to characterize and replicate the structure and function of innovator drugs. Key therapeutic areas included rheumatoid arthritis, inflammatory bowel disease, and psoriasis. The goal was to improve patient access to essential medications and reduce healthcare costs. The company had a pipeline of biosimilar product candidates, including versions of Remicade (infliximab), Humira (adalimumab), Actemra (tocilizumab), Soliris, and SIMPONI. Epirus collaborated with partners like Livzon Mabpharm Inc. and Polpharma S.A. to expand its reach and accelerate product development. The company's focus was on providing affordable and effective treatments for patients with chronic conditions.